strong nish strong outlook
db take reiter buy rate rais price
abbott report anoth strong quarter beat street estim
top bottom line compar constant currenc growth repres
second quarter acceler organ growth follow growth
believ inect low-singl digit mid-singl digit growth
sustain driven new product launch medic devic
diagnost segment well strong industri trend establish pharma
believ abbott necessari piec drive consist least mid-singl
digit top line doubl digit bottom line growth reiter buy rate
given posit result strength underli busi
expect continu rais price target reect target
multipl ep estim sinc spin-
brand pharmaceut busi januari share
trade averag premium target multipl appli
premium multipl multipl also consist
trade trail basi ep high-
growth med-tech peer trade
price jan usd
guidanc build strong second half
abbott provid organ growth guidanc impli continu
strong organ growth perform except nutrit
segment top line strength broad base establish pharmaceut
diagnost medic devic expect grow least mid-to-high singl
digit compar constant currenc basi full year ep guidanc
impli growth growth exclud accret
aler increment accret st jude abbott continu reinvest
back busi came away earn call increment
comfort regard integr st jude aler perform
base busi thu view guidanc realist achiev
watch
within medic devic segment us launch freestyl libr
meaning growth driver especi follow receipt
medicar coverag neuromodul busi continu
grow market rate compani grow least line
market rhythm manag portfolio follow fda approv
mri-compat crt-d
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
within diagnost expect continu momentum alin
platform launch europ well unit state
within establish pharmaceut expect see continu high-
singl digit low doubl digit given abbott presenc key
emerg market economi strong underli dynam
expect nutrit segment remain headwind overal growth
howev believ segment growth rate improv
forecast ratio
take quartervari analysi surpris product sale trend sale ep beat street posit earn outlook reflect doubl digit growth mex strong product pipelin sever area continu weak pediatr nutrtit challeng market condit intern countriesestablish recappoint tabl exclud sale ex-fx compar chang basi sale factset fs consensu dbe compar oper sale beat primarili driven higher sale gross margin lower expect off-set lower spend ep factset fs dbe also high end previou guidanc rang changeaddit detail quarter million except per share data chang sale constant currenc basi unless otherwis full year adjust ep expect reflect growth mid-point compar favor street estim dbe gaap ep expect abbott expect adjust cash ep street estim dbe benefit tax reform legisl tax rate expect reduc total sale us sale sale compar oper intern countri growth adult nutrit driven nutrit brand ensur scale test area primarili us america sale countri led favor time sale fourth vascular adjust gross margin adjust sg expens expens oper margin tax rate ine share count adjust ep ahead street estim dbe januari
manag provid guidanc initi full year guidanc
full year abbott provid organ growth guidanc impli
continu strong organ growth perform segment
manag anticip follow compar constant currenc
establish pharmaceut high-singl digit sale growth
full year
nutrit low-singl digit sale growth full year
figur abbott sale segment
diagnost mid-singl digit growth mid-to-high singl
digit growth
medic devic mid-to-high singl digit sale growth
full year
manag anticip gross margin remain similar rang
somewhat sg expens percent sale expect
slightli expens percent sale expect
increas
full year ep guidanc impli growth growth
exclud accret aler increment accret st jude
ep expect rang
cardiovasc
gross expens expens loss net incom dilut adjust januari
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur
primari subject research pleas see recent publish compani report visit global disclosur look-up page websit http //gm db com/ger/disclosure/
disclosuredirectori eqsr asid within report import conict disclosur also found http //gm db com/equ disclosur lookup legal
tab investor strongli encourag review inform invest
import disclosur requir regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
import disclosur requir non-u regul explanatori note
within past year deutsch bank and/or aliat manag co-manag public privat
oer compani receiv fee
deutsch bank and/or aliat make market equiti secur issu compani
deutsch bank and/or aliat receiv compens compani provis
invest bank nancial advisori servic within past year
deutsch bank and/or aliat expect receiv intend seek compens invest bank
servic compani next three month
deutsch bank and/or aliat receiv non-invest bank relat compens
compani within past year
compani client deutsch bank secur inc within past year time
import disclosur requir non-u regul
